Distant metastasis-free survival, a secondary endpoint, was also significantly improved versus placebo (HR=0.76 [95.8% CI: 0.64-0.92; p=0.002]) and had five-year DMFS rates of 48.3% and 38.9% in the Yervoy and placebo groups, respectively.
Researchers at Vanderbilt and the University of Michigan have shown that an at-home urine test for prostate cancer screening is highly accurate.
